Amy E. Chang

机构：Eli Lilly (United States) · ORCID：0000-0003-4646-0558

发表论文 49 篇 · 总被引 3550 次 · h-index 16

代表论文

• Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma (2012 · Cancer Cell · 被引 2225)
• RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma (2015 · Cell · 被引 209)
• A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk (2018 · Diabetes Care · 被引 177)
• Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells (2010 · Clinical Cancer Research · 被引 145)
• Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer (2015 · Cancer Research · 被引 105)
• Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries (2019 · Diabetes Care · 被引 95)